ClinicalTrials.gg
Active, not recruitingNCT07246889Updated May 4, 2026

Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)

A Phase 3 interventional study of AHB-137 and Placebo in Chronic Hepatitis B, sponsored by Ausper Biopharma Co., Ltd.. Active, not recruiting at 28 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Ausper Biopharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
577
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic — 6 open to participants now, 8 under way, 1 of them phase 3. Hepatitis B Virus Antisense Oligonucleotide AHB-137 · Hepatitis B, Chronic.

Enrollment
Largest of 11
577 · median 86
Started
2025
with 3 others
Phase 3
Only one
of the 11
Registered
6th of 11
by date
Lead sponsor
8 of 11
Ausper Biopharma Co., Ltd.

Among the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, this one has the largest enrollment, is one of 4 that started in 2025, is the only one in phase 3, and was the 6th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

6 of the 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About Hepatitis B Virus Antisense Oligonucleotide AHB-137

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Hepatitis B Virus Antisense Oligonucleotide AHB-137 in Hepatitis B, Chronic, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, multicenter phase 3 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

Keywords

  • Hepatitis B, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants voluntarily participate in the study, and sign the Form (ICF) prior to screening, able to complete the study according to the protocol;
  • At least 18 years of age at the time of signing the ICF;
  • met the requirements;
  • HBeAg negative at screening;
  • or HBV DNA positive for at least 6 months;
  • Meet relevant requirements for NAs treatment;
  • 100 IU/mL \< HBsAg ≤ 3000 IU/mL, HBV DNA \< 100 IU/mL and liver function indicators meet the requirements;
  • Effective as required.

Exclusion criteria

Exclusion Criteria:

  • abnormalities other than a history of chronic infection;
  • Concomitant clinically significant other liver diseases;
  • Previous/current manifestations of hepatic decompensation;
  • Significant hepatic fibrosis or cirrhosis;
  • Presence of protocol-specified laboratory abnormalities;
  • History of or ongoing assessment of possible malignancy;
  • Those allergic to AHB-137 or its components;
  • Participants with recent major trauma or major surgery, or planning surgery;
  • Those who are participating in another clinical trial, or have not undergone a protocol-specified prior to this study;
  • Prior/current use of prohibited medications;
  • Inappropriate for participation in this trial as judged by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
577 participants (actual)

Study arms

  • Experimental
    AHB-137

    Drug: AHB-137 · Drug: NA therapy

  • Placebo comparator
    Placebo

    Drug: Placebo · Drug: NA therapy

Interventions

  • AHB-137 will be injected weekly by subcutaneous injection. There are 2 leading doses on day 4 and day 11.

  • DrugPlacebo

    Placebo will be injected weekly by subcutaneous injection.Two additional doses given on day 4 and day 11.

  • DrugNA therapy

    NA will be the background therapy. After stopping the AHB-137 or placebo injection, continue for another 12 weeks.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ) at the 24th week after all treatment for CHB was discontinued

    Time frame: 24 weeks after discontinuation of all CHB treatment

Secondary outcomes

  1. Proportion of participants with persistent HBV DNA < LLOQ .

    Time frame: 24 weeks after discontinuation of all CHB treatment

  2. Proportion of participants with persistent HBsAg < LOD and HBV DNA < LLOQ

    Time frame: Up to 60 weeks

  3. Concentration of HBsAg, HBV DNA, HBV RNA, HBcrAg, HBsAb,HBeAg, HBeAb

    Time frame: Up to 60 weeks

  4. Relapse rate after discontinuation of NAs therapy.

    Time frame: Up to 60 weeks

  5. Safety: Number and percentage of participants with detectable anti-drug antibodies (ADA).

    Time frame: Up to 60 weeks

  6. Safety: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAE) and clinically significant examination results.

    Time frame: Up to 60 weeks

  7. Plasma concentrations of AHB-137.

    Time frame: Up to 60 weeks

  8. Sequencing of the Viral DNA and/or viral RNA analysis for detection of drug resistance in the target region of AHB-137

    Time frame: Up to 60 weeks

  9. Change from baseline in EuroQol Five-Dimension Five-Level Scale (EQ-5D-5L) scores in participants with HBV infection.

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

    Time frame: Up to 60 weeks

  10. Changes of the hepatitis B quality of life (HBQOL) instrument in participants compared with baseline.

    This scale has 31 items, including 7 dimensions: psychological status, expected anxiety, vitality, shame, infectivity, health vulnerability, and viral response. Each item is scored on a 5-point scale, with higher scores indicating a more severe impact of hepatitis B on quality of life.

    Time frame: Up to 60 weeks

07

Study locations

28 sites
  • AusperBio Investigational Site
    Hefei, Anhui, China
  • AusperBio Investigational Site
    Beijing, Beijing Municipality, China
  • AusperBio Investigational Site
    Chongqing, Chongqing Municipality, China
  • AusperBio Investigational Site
    Fuzhou, Fujian, China
  • AusperBio Investigational Site
    Xiamen, Fujian, China
  • AusperBio Investigational Site
    Lanzhou, Gansu, China
  • AusperBio Investigational Site
    Foshan, Guangdong, China
  • AusperBio Investigational Site
    Guangzhou, Guangdong, China
  • AusperBio Investigational Site
    Shenzhen, Guangdong, China
  • AusperBio Investigational Site
    Liuzhou, Guangxi, China
  • AusperBio Investigational Site
    Nanning, Guangxi, China
  • AusperBio Investigational Site
    Guiyang, Guizhou, China
  • AusperBio Investigational Site
    Zunyi, Guizhou, China
  • AusperBio Investigational Site
    Haikou, Hainan, China
  • AusperBio Investigational Site
    Zhengzhou, Henan, China
  • AusperBio Investigational Site
    Wuhan, Hubei, China
  • AusperBio Investigational Site
    Changsha, Hunan, China
  • AusperBio Investigational Site
    Nanjing, Jiangsu, China
  • AusperBio Investigational Site
    Zhenjiang, Jiangsu, China
  • AusperBio Investigational Site
    Nanchang, Jiangxi, China
  • AusperBio Investigational Site
    Changchun, Jilin, China
  • AusperBio Investigational Site
    Shenyang, Liaoning, China
  • AusperBio Investigational Site
    Shanghai, Shanghai Municipality, China
  • AusperBio Investigational Site
    Taiyuan, Shanxi, China
  • AusperBio Investigational Site
    Xi’an, Shanxi, China
  • AusperBio Investigational Site
    Chengdu, Sichuan, China
  • AusperBio Investigational Site
    Kunming, Yunnan, China
  • AusperBio Investigational Site
    Hangzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.

Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2025
First posted
Nov 24, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Dec 18, 2026
CompletionEst.
Oct 31, 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07246889
Responsible party
Sponsor
First posted
Nov 24, 2025
Start date
Aug 12, 2025
Primary completion
Dec 18, 2026 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
May 4, 2026

Study contacts

AusperBio Clinical Trials
study director · AusperBio Investigational Site

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hepatitis B Virus Antisense Oligonucleotide AHB-137

Start the discussion